PainReform (NASDAQ:PRFX) Announces Quarterly Earnings Results

PainReform (NASDAQ:PRFX) issued its earnings results on Thursday. The company reported ($0.98) EPS for the quarter, FiscalAI reports.

PainReform Stock Performance

Shares of NASDAQ:PRFX remained flat at $2.36 during midday trading on Friday. 40,124 shares of the company were exchanged, compared to its average volume of 549,010. The firm has a market cap of $951,080.00, a price-to-earnings ratio of 0.00 and a beta of 0.55. PainReform has a fifty-two week low of $2.08 and a fifty-two week high of $17.95. The stock’s fifty day moving average price is $3.17 and its two-hundred day moving average price is $4.64.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, PainReform has a consensus rating of “Sell”.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.